Technological advances over the past decade have made precision genetic diagnosis available to many patients. The findings of a new study demonstrate that genetic diagnosis in epilepsy can lead to changes in clinical management that manifest as positive outcomes for the patient. The results herald a new era in which precision diagnosis will lead to precision medicine.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
De novo ADGRV1 variant in a patient with ictal asystole provides novel clues for increased risk of SUDEP
Acta Epileptologica Open Access 24 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Helbig, I., Heinzen, E. L. & Mefford, H. C. Primer part 1 — the building blocks of epilepsy genetics. Epilepsia 57, 861–868 (2016).
McKnight, D. et al. Genetic testing to inform epilepsy treatment management from an international study of clinical practice. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2022.3651 (2022).
Bayat, A. et al. Impact of genetic testing on therapeutic decision-making in childhood-onset epilepsies — a study in a tertiary epilepsy center. Neurotherapeutics 19, 1353–1367 (2022).
Johannesen, K. M. et al. Utility of genetic testing for therapeutic decision-making in adults with epilepsy. Epilepsia 61, 1234–1239 (2020).
de Lange, I. M. et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia 59, 1154–1165 (2018).
van der Sanden, B. P. G. H. et al. The performance of genome sequencing as a first-tier test for neurodevelopmental disorders. Eur. J. Hum. Genet. https://doi.org/10.1038/s41431-022-01185-9 (2022).
Oates, S. et al. Incorporating epilepsy genetics into clinical practice: a 360° evaluation. NPJ Genom. Med. 3, 13 (2018).
Hayden, E. C. Drug for rare epilepsy causes brain side effect. The New York Times https://www.nytimes.com/2022/10/26/health/gene-treatment-epilepsy-antisense-brain.html (2022). Accessed October 2022
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Johannesen, K.M. From precision diagnosis to precision treatment in epilepsy. Nat Rev Neurol 19, 69–70 (2023). https://doi.org/10.1038/s41582-022-00756-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00756-0
This article is cited by
-
De novo ADGRV1 variant in a patient with ictal asystole provides novel clues for increased risk of SUDEP
Acta Epileptologica (2023)
